Cutting-edge treatments to be fast-tracked to patients through international collaborations

The UK will work together with USA, Canada, Australia, Switzerland, Singapore and Brazil under Project Orbis and Access Consortium for regulatory reviews of new medicines after the EU transition period. The MHRA will retain the final authority for decisions for the UK.

Source:

Department of Health and Social Care